Immunoglobulin deficiency with increased immunoglobulin M in three siblings: effect of long-term immunoglobulin therapy

1988 ◽  
Vol 148 (3) ◽  
pp. 215-217 ◽  
Author(s):  
L. Mar�di ◽  
I. Szab� ◽  
�. Kalm�r
Keyword(s):  
Immunoglobulin Therapy ◽  
Immunoglobulin M ◽  
Immunoglobulin Deficiency

scholarly journals Twelve-Year-Old Girl with Primary Biliary Cirrhosis

2012 ◽  
Vol 2012 ◽  
pp. 1-3 ◽  
Author(s):  
Ivana Kitic ◽  
Aleksandra Boskovic ◽  
Ivica Stankovic ◽  
Dragan Prokic
Keyword(s):  
Primary Biliary Cirrhosis ◽  
World Literature ◽  
Pediatric Patients ◽  
Immunoglobulin M ◽  
Cholestatic Liver Disease ◽  
Biliary Cirrhosis ◽  
Antimitochondrial Antibodies ◽  
Biochemical Tests ◽  
Autoimmune Etiology

Primary biliary cirrhosis (PBC) is a slowly progressive cholestatic liver disease of autoimmune etiology. The initial presentation of PBC is varies from asymptomatic, abnormal liver biochemical tests to overt cirrhosis. Unlike other autoimmune liver diseases, PBC has rarely been reported in childhood. We report a case of primary biliary cirrhosis in a 12-year-old girl. In addition to characteristic histology features, strongly positive antimitochondrial antibodies, increased liver enzyme levels, increased serum quantitative immunoglobulin M levels, and cholestasis were discovered. She had been treated with ursodeoxycholic acid. In the world literature, we found only few pediatric patients of primary biliary cirrhosis. Aetiology, pathogenesis, the long-term natural history, and prognosis remain obscure. Due to increased awareness of early-onset PBC, rather than typical older ones, further pediatric cases may be discovered.

scholarly journals SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19

2020 ◽  
Author(s):  
Jun Wu ◽  
Boyun Liang ◽  
Cunrong Chen ◽  
Hua Wang ◽  
Yaohui Fang ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Disease Onset ◽  
Immunoglobulin M ◽  
Late Time ◽  
N Protein ◽  
Humoral Immune ◽  
Humoral Immune Responses ◽  
First World ◽  
Observation Period

Long-term antibody responses and neutralizing activities following SARS-CoV-2 infections have not yet been elucidated. We quantified immunoglobulin M (IgM) and G (IgG) antibodies recognizing the SARS-CoV-2 receptor-binding domain (RBD) of the spike (S) or the nucleocapsid (N) protein, and neutralizing antibodies during a period of six months following COVID-19 disease onset in 349 symptomatic COVID-19 patients, which were among the first world-wide being infected. The positivity rate and magnitude of IgM-S and IgG-N responses increased rapidly. High levels of IgM-S/N and IgG-S/N at 2-3 weeks after disease onset were associated with virus control and IgG-S titers correlated closely with the capacity to neutralize SARS-CoV-2. While specific IgM-S/N became undetectable 12 weeks after disease onset in most patients, IgG-S/N titers showed an intermediate contraction phase, but stabilized at relatively high levels over the six months observation period. At late time points the positivity rates for binding and neutralizing SARS-CoV-2-specific antibodies was still over 70%. Taken together, our data indicate sustained humoral immunity in recovered patients who suffer from symptomatic COVID-19, suggesting prolonged immunity.

Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis

2008 ◽  
Vol 14 (9) ◽  
pp. 1208-1213 ◽  
Author(s):  
M Thangarajh ◽  
J Gomez-Rial ◽  
AK Hedström ◽  
J Hillert ◽  
JC Alvarez-Cermeño ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Median Time ◽  
Immunoglobulin M ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Relapsing Remitting ◽  
Specific Immunoglobulin ◽  
Long Term Prognosis ◽  
Relapsing Remitting Multiple Sclerosis

Background and Objective The presence of lipid-specific immunoglobulin M bands in the cerebrospinal fluid (CSF) predicts an aggressive course in patients with relapsing–remitting multiple sclerosis (MS) during early stages of the disease. This study examined whether it is also a predictor of long-term prognosis in MS. Methods Eighty-one patients with MS and 22 headache controls were analyzed for anti-lipid IgM reactivity in CSF samples. The correlation between the presence of lipid-specific immunoglobulin M bands in CSF and disease progression was assessed in patients with MS who had been followed longitudinally for, on average, more than 11 years. Results Lipid-specific immunoglobulin M bands were detected in the CSF of 24 of 81 patients with MS and were absent in the CSF of all headache controls. Median time to conversion to a secondary progressive course was 11 years in patients with bands and 22 years in patients without bands. Median time to an Expanded Disability Status Scale score of 4 was 14 years in patients with bands and 24 years in patients without bands. Conclusion The presence of lipid-specific immunoglobulin M bands in CSF predicts a more adverse long-term outcome in patients with MS; it may thus define a subset of patients who might benefit from aggressive treatment during the early phase of the disease.

scholarly journals SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Jun Wu ◽  
Boyun Liang ◽  
Cunrong Chen ◽  
Hua Wang ◽  
Yaohui Fang ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Disease Onset ◽  
Immunoglobulin M ◽  
Late Time ◽  
N Protein ◽  
Contraction Phase ◽  
Humoral Immune ◽  
Humoral Immune Responses ◽  
Observation Period

AbstractLong-term antibody responses and neutralizing activities in response to SARS-CoV-2 infection are not yet clear. Here we quantify immunoglobulin M (IgM) and G (IgG) antibodies recognizing the SARS-CoV-2 receptor-binding domain (RBD) of the spike (S) or the nucleocapsid (N) protein, and neutralizing antibodies during a period of 6 months from COVID-19 disease onset in 349 symptomatic COVID-19 patients who were among the first be infected world-wide. The positivity rate and magnitude of IgM-S and IgG-N responses increase rapidly. High levels of IgM-S/N and IgG-S/N at 2-3 weeks after disease onset are associated with virus control and IgG-S titers correlate closely with the capacity to neutralize SARS-CoV-2. Although specific IgM-S/N become undetectable 12 weeks after disease onset in most patients, IgG-S/N titers have an intermediate contraction phase, but stabilize at relatively high levels over the 6 month observation period. At late time points, the positivity rates for binding and neutralizing SARS-CoV-2-specific antibodies are still >70%. These data indicate sustained humoral immunity in recovered patients who had symptomatic COVID-19, suggesting prolonged immunity.

Sign in / Sign up

Export Citation Format

Share Document